文献速递类风湿关节炎

JAK抑制剂在类风湿关节炎患者中的安全性证据日益增多

Growing evidence of the safety of JAK inhibitors in patients with rheumatoid arthritis.
PubMed 文献 · Rheumatology (Oxford) · 2019-01-01

本文综述了托法替布和巴瑞替尼两种JAK抑制剂在RA治疗中的安全性证据。随机对照试验显示其疗效与生物DMARDs相当,但真实世界证据仍需建立。感染筛查监测与生物DMARDs无本质差异,带状疱疹风险可能普遍增加,恶性肿瘤风险未见增加信号,罕见严重不良事件需持续药物警戒。

要点

  • JAK抑制剂疗效与生物DMARDs相当,安全性已在随机对照试验及长期扩展研究中证实。
  • 带状疱疹风险增加可能是所有JAK抑制剂的共同特征。
  • 血栓栓塞、胃肠穿孔、间质性肺病等罕见事件需积累病例并持续药物警戒。

核心结论

  • JAK抑制剂在RA患者中的安全性证据不断积累,但真实世界证据尚待建立以桥接随机对照试验与临床实践之间的差距。

研究设计与样本

  • 本文为综述,汇总随机对照试验及其长期扩展研究中托法替布和巴瑞替尼的安全性数据。

主要发现

  • 随机对照试验显示JAK抑制剂疗效与生物DMARDs相当。
  • 感染筛查、预防和监测方面JAK抑制剂与生物DMARDs无本质差异。
  • 带状疱疹风险增加可能是所有JAK抑制剂的共同特征。
  • 接受JAK抑制剂治疗的RA患者未见恶性肿瘤风险增加的迹象。

临床怎么用

  • JAK抑制剂与生物DMARDs采用相同的感染筛查、预防和监测策略。
  • 需关注带状疱疹风险,并对血栓栓塞、胃肠穿孔和间质性肺病等罕见严重事件保持药物警戒。

局限性

  • 真实世界证据尚待建立。
  • 血栓栓塞、胃肠穿孔和间质性肺病等相对罕见的严重不良事件需积累更多病例方可评估临床环境中的风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

To facitinib and baricitinib are two of the currently available Janus kinase (JAK) inhibitors for the treatment of patients with RA. Randomized controlled trials have shown that these JAK inhibitors are as efficacious as biological DMARDs. Safety profiles of these JAK inhibitors in randomized controlled trials and their long-term extension studies have been demonstrated; however, real world evidence remains to be established to bridge the gap between randomized controlled trials and rheumatology clinics. Fundamentally, no difference in the screening, prevention, and monitoring of infections between JAK inhibitors and biological DMARDs exists. However, increased risk of herpes zoster is probably common to all JAK inhibitors. No indication of increased risk for malignancy in patients with RA treated with JAK inhibitors has been reported. To evaluate risks of relatively rare serious adverse events such as thromboembolic events, gastrointestinal perforation, and interstitial lung disease in clinical settings, accumulation of cases with these events are needed. Continuous pharmacovigilance activity is absolutely warranted to establish the safety of JAK inhibitors in patients with RA and other rheumatic diseases.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. Harigai M. Growing evidence of the safety of JAK inhibitors in patients with rheumatoid arthritis. Rheumatology (Oxford). 2019. PMID: 30806708. doi:10.1093/rheumatology/key287

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。